Roche will unveil more than 45 ophthalmology abstracts at ARVO 2026, headlined by real-world data showing that Vabysmo improves retinal anatomy and dries the retina in neovascular AMD and diabetic macular edema, new evidence that Susvimo’s continuous ranibizumab delivery can sustain disease control with fewer visits, and first Phase 2 readouts for the intravitreal anti–IL-6 antibody vamikibart in DME. The slate spans five retinal conditions, including RVO, GA, and uveitic macular edema, positioning Roche’s retina franchise across anti-VEGF/Ang-2 biology, continuous delivery, and inflammation pathways.
The strategic through-line is unmistakable: reducing treatment burden while broadening mechanisms of action. In a market reshaped by extended-interval anti-VEGFs and tightening clinic capacity, the question is no longer who wins on noninferiority; it is who can prove durable disease control in the messiness of routine care and segment patients to the right modality at the right time. Roche is betting that AI-enabled real-world imaging, procedure-based delivery, and immunomodulation can collectively tilt the curve on outcomes and economics.
For patients and retina practices, the implications are immediate. Real-world “drying” validated across treatment-naïve and previously treated eyes is the metric many clinicians use as a proxy for durability and visual outcomes, and it travels more convincingly into community settings than trial-only endpoints. If these data hold, HCPs gain confidence to extend dosing, and clinics reclaim scarce chair time. Susvimo introduces a different operational equation: a one-time implant with refills versus serial injections. That promises relief for high-burden patients but shifts workload to surgical time, demands training, and raises site-of-service reimbursement questions that Market Access teams must solve. Patient preference signals and pharmacokinetic modeling presented at ARVO will be scrutinized for how they translate into adherence and clinic workflow.
Payers will parse two themes: evidence of lasting anatomical control that reduces visit frequency and downstream resource use, and the case for device-based delivery economics. Real-world outcomes, especially those quantified by deep learning analysis of OCTs, increasingly inform coverage policies and renewal criteria. If Roche can link drying and fewer visits to reduced total cost of care, Vabysmo could maintain its edge against aflibercept 8 mg and biosimilars, while Susvimo may justify procedure and facility fees for carefully selected segments. The RVO data add breadth where coverage in community retina practices often lags, potentially protecting share across indications.
Competition is intensifying across modalities. High-dose aflibercept presses on interval length and price. Sustained delivery contenders and TKIs are racing to demonstrate fewer touchpoints with acceptable safety. In this context, vamikibart’s move into DME and UME, including combination data with ranibizumab, signals a layered approach that acknowledges inflammation as a co-driver of edema and refractoriness. If safety and vision gains prove durable, an IL-6 pathway option with orphan designation in UME could open a differentiated reimbursable niche and invite step-through algorithms for refractory disease.
The data strategy matters as much as the molecules. AI-quantified OCT endpoints and prospective global RWE, if standardized and reproducible, can populate payer dossiers and support international label expansions. With Susvimo branded as Contivue in the EU and EMA review underway, harmonizing evidence for device coverage and perioperative protocols will be central to launch sequencing and contracting.
What to watch now: the magnitude of anatomical drying and dosing interval extension achieved in practice, the procedural and safety profile of Susvimo in high-burden eyes under real-world conditions, and whether vamikibart’s Phase 2 efficacy is compelling enough to anchor a combination-ready, inflammation-forward strategy. The competitive question is whether Roche can convert a narrative of durability and multimodal control into differentiated access and a new retina care operating model before rivals close the convenience gap.
Source link: https://www.globenewswire.com/news-release/2026/04/30/3284418/0/en/Roche-to-present-extensive-data-showcasing-its-industry-leading-ophthalmology-portfolio-at-ARVO-2026.html
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
